Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates

Journal of Virology

Volumn 82, Issue 6, 2008, Pages 2975-2988

  Mooij, Petra ^a   Balla Jhagjhoorsingh, Sunita S ^a,e   Koopman, Gerrit ^a   Beenhakker, Niels ^a   Van Haaften, Patricia ^a,f   Baak, Ilona ^a,g   Nieuwenhuis, Ivonne G ^a   Kondova, Ivanela ^a   Wagner, Ralf ^b   Wolf, Hans ^b   Gómez, Carmen E ^c   Nájera, José L ^c   Jiménez, Victoria ^c   Esteban, Mariano ^c   Heeney, Jonathan L ^a,d  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g NETHERLANDS FORENSIC INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; NUCLEOTIDE SEQUENCE; POXVIRUS; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VACCINIA VIRUS; VIRUS LOAD;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIGENS; HIV-1; IMMUNOPHENOTYPING; MACACA MULATTA; POXVIRIDAE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; POXVIRIDAE; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

EID: 40149094782     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02216-07     Document Type: Article

References (101)

1. Albert, M. L. 2004. Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat. Rev. Immunol. 4:223-231.
2. Amara, R. R., C. Ibegbu, F. Villinger, D. C. Montefiori, S. Sharma, P. Nigam, Y. Xu, H. M. McClure, and H. L. Robinson. 2005. Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/ MVA-vaccinated macaques. Virology 343:246-255.
3. Amara, R. R., K. Patel, G. Niedziela, P. Nigam, S. Sharma, S. I. Staprans, D. C. Montefiori, L. Chenareddi, J. G. Herndon, H. L. Robinson, H. M. McClure, and F. J. Novembre. 2005. A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. S. Virol. 79:15356-15367.
4. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
5. Anel, A., A. Bosque, J. Naval, A. Pineiro, L. Larrad, M. A. Alava, and M. J. Martinez-Lorenzo. 2007. Apo2L/TRAIL and immune regulation. Front. Biosci. 12:2074-2084.
6. - memory T-helper cells. AIDS 18:837-848.
7. mac251: dependence on route of challenge exposure. J. Virol. 72:4170-4182.
8. Bertley, F. M., P. A. Kozlowski, S. W. Wang, J. Chappelle, J. Patel, O. Sonuyi, G. Mazzara, D. Montefiori, A. Carville, K. G. Mansfield, and A. Aldovini. 2004. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol. 172:3745-3757.
9. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, M. Roederer, and R. A. Koup. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789.
10. Blachère, N. E., R. B. Darnell, and M. L. Albert. 2005. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol. 3:e185.
11. + CD4 T cell responses is associated with nonprogression in HIV-1 infection. J. Immunol. 169:6376-6385.
12. + T cells in vivo. J. Virol. 80:6801-6809.
13. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
14. Carrington, M., and S. J. O'Brien. 2003. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54:535-551.
15. Cebere, I., L. Dorrell, H. McShane, A. Simmons, S. McCormack, C. Schmidt, C. Smith, M. Brooks, J. E. Roberts, S. C. Darwin, P. E. Fast, C. Conlon, S. Rowland-Jones, A. J. McMichael, and T. Hanke. 2006. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24:417-425.
16. Champagne, P., G. S. Ogg, A. S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G. P. Rizzardi, S. Fleury, M. Lipp, R. Forster, S. Rowland-Jones, R. P. Sekaly, A. J. McMichael, and G. Pantaleo. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410:106-111.
17. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66:7517-7521.
18. Corbett, M., W. M. Bogers, J. L. Heeney, S. Gerber, C. Genin, A. Didierlaurent, H. Oostermeijer, R. Dubbes, G. Braskamp, S. Lerondel, C. E. Gomez, M. Esteban, I. Kondova, P. Mooij, S. S. Balla-Jhagjhoorsingh, N. Beenhakker, G. Koopman, S. Van der Burg, J. P. Kraehenbuhl, and A. Le Pape. Aerosol immunization with NYVAC and MVA vectored vaccines: simple, safe and immunogenic. Proc. Natl. Acad. Sci. USA in press.
19. 89.6P challenge in rhesus macaques. J. Virol. 81:3414-3427.
20. Didierlaurent, A., J. C. Ramirez, M. Gherardi, S. C. Zimmerli, M. Graf, H. A. Orbea, G. Pantaleo, R. Wagner, M. Esteban, J. P. Kraehenbuhl, and J. C. Sirard. 2004. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22: 3395-3403.
21. + T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J. Virol. 77:11563-11577.
22. Dorrell, L., H. Yang, B. Ondondo, T. Dong, K. di Gleria, A. Suttill, C. Conlon, D. Brown, P. Williams, P. Bowness, N. Goonetilleke, T. Rostron, S. Rowland-Jones, T. Hanke, and A. McMichael. 2006. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J. Virol. 80:4705-4716.
23. Douek, D. C., J. M. Brenchley, M. R. Betts, D. R. Ambrozak, B. J. Hill, Y. Okamoto, J. P. Casazza, J. Kuruppu, K. Kunstman, S. Wolinsky, Z. Grossman, M. Dybul, A. Oxenius, D. A. Price, M. Connors, and R. A. Koup. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417:95-98.
24. Egan, M. A., S. Y. Chong, S. Megati, D. C. Montefiori, N. F. Rose, J. D. Boyer, M. K. Sidhu, J. Quiroz, M. Rosati, E. B. Schadeck, G. N. Pavlakis, D. B. Weiner, J. K. Rose, Z. R. Israel, S. A. Udem, and J. H. Eldridge. 2005. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res. Hum. Retrovir. 21:629-643.
25. Feinberg, M. B., and J. P. Moore. 2002. AIDS vaccine models: challenging challenge viruses. Nat. Med. 8:207-210.
26. Fischer, W., S. Perkins, J. Theiler, T. Bhattacharya, K. Yusim, R. Funkhouser, C. Kuiken, B. Haynes, N. L. Letvin, B. D. Walker, B. H. Hahn, and B. T. Korber. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13:100-106.
27. Frahm, N., S. Adams, P. Kiepiela, C. H. Linde, H. S. Hewitt, M. Lichterfeld, K. Sango, N. V. Brown, E. Pae, A. G. Wurcel, M. Altfeld, M. E. Feeney, T. M. Allen, T. Roach, M. A. St. John, E. S. Daar, E. Rosenberg, B. Korber, F. Marincola, B. D. Walker, P. J. Goulder, and C. Brander. 2005. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J. Virol. 79:10218-10225.
28. Frahm, N., P. Kiepiela, S. Adams, C. H. Linde, H. S. Hewitt, K. Sango, M. E. Feeney, M. M. Addo, M. Lichterfeld, M. P. Lahaie, E. Pae, A. G. Wurcel, T. Roach, M. A. St. John, M. Altfeld, F. M. Marincola, C. Moore, S. Mallal, M. Carrington, D. Heckerman, T. M. Allen, J. I. Mullins, B. T. Korber, P. J. Goulder, B. D. Walker, and C. Brander. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7:173-178.
29. Franchini, G., S. Gurunathan, L. Baglyos, S. Plotkin, and J. Tartaglia. 2004. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3:S75-S88.
30. Gherardi, M. M., and M. Esteban. 2005. Recombinant poxviruses as mucosal vaccine vectors. J. Gen. Virol. 86:2925-2936.
31. Gómez, C. E., J. L. Najera, E. Domingo-Gil, L. Ochoa-Callejero, G. Gonzalez-Aseguinolaza, and M. Esteban. 2007. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J. Gen. Virol. 88:2473-2478.
32. Gómez, C. E., J. L. Najera, E. P. Jimenez, V. Jimenez, R. Wagner, M. Graf, M. J. Frachette, P. Liljestrom, G. Pantaleo, and M. Esteban. 2007. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC coexpressing in a single locus the HIV-1(BX08) gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25:2863-2885.
33. Gómez, C. E., J. L. Najera, V. Jimenez, K. Bieler, J. Wild, L. Kostic, S. Heidari, M. Chen, M. J. Frachette, G. Pantaleo, H. Wolf, P. Liljestrom, R. Wagner, and M. Esteban. 2007. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25:1969-1992.
34. + T-cell epitopes. J. Virol. 80:4717-4728.
35. Guerra, S., L. A. Lopez-Fernandez, R. Conde, A. Pascual-Montano, K. Harshman, and M. Esteban. 2004. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J. Virol. 78:5820-5834.
36. Guerra, S., L. A. Lopez-Fernandez, A. Pascual-Montano, J. L. Najera, A. Zaballos, and M. Esteban. 2006. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-κB-responsive genes in infected HeLa cells. J. Virol. 80:985-998.
37. Guerra, S., J. L. Najera, J. M. Gonzalez, L. Lopez, N. Climent, J. M. Gatell, T. Gallart, and M. Esteban. 2007. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J. Virol. 81:8707-8721.
38. Hanke, T., R. V. Samuel, T. J. Blanchard, V. C. Neumann, T. M. Allen, J. E. Boyson, S. A. Sharpe, N. Cook, G. L. Smith, D. I. Watkins, M. P. Cranage, and A. J. McMichael. 1999. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:7524-7532.
39. Harari, A., P. A. Bart, W. Stöhr, G. Tapia, M. Garcia, E. Medjitna-Rais, S. Burnet, O. Erlwein, T. Barber, C. Moog, P. Liljestrom, R. Wagner, H. Wolf, J. P. Kraehenbuhl, M. Esteban, J. L. Heeney, M. J. Frachette, J. Tartaglia, S. McCormack, A. Babiker, J. Weber, and G. Pantaleo. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces vigorous, broad, polyfunctional and long-lasting T-cell responses. J. Exp. Med. 205: 63-67.
40. Heeney, J. L., and S. A. Plotkin. 2006. Immunological correlates of protection from HIV infection and disease. Nat. Immunol. 7:1281-1284.
41. Hel, Z., J. Nacsa, E. Tryniszewska, W. P. Tsai, R. W. Parks, D. C. Montefiori, B. K. Felber, J. Tartaglia, G. N. Pavlakis, and G. Franchini. 2002. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J. Immunol. 169:4778-4787.
42. Hel, Z., W. P. Tsai, A. Thornton, J. Nacsa, L. Giuliani, E. Tryniszewska, M. Poudyal, D. Venzon, X. Wang, J. Altman, D. I. Watkins, W. Lu, A. von Gegerfelt, B. K. Felber, J. Tartaglia, G. N. Pavlakis, and G. Franchini. 2001. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. 167:7180-7191.
43. Im, E. J., J. P. Nkolola, K. di Gleria, A. J. McMichael, and T. Hanke. 2006. Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur. J. Immunol. 36:2574-2584.
44. Inaba, K., S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M. Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, M. Albert, N. Bhardwaj, I. Mellman, and R. M. Steinman. 1998. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 188:2163-2173.
45. Kanesa-Thasan, N., J. J. Smucny, C. H. Hoke, D. H. Marks, E. Konishi, I. Kurane, D. B. Tang, D. W. Vaughn, P. W. Mason, and R. E. Shope. 2000. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-non-immune and vaccinia-immune humans. Vaccine 19:483-491.
46. Kannanganat, S., B. G. Kapogiannis, C. Ibegbu, L. Chennareddi, P. Goepfert, H. L. Robinson, J. Lennox, and R. R. Amara. 2007. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J. Virol. 81:12071-12076.
47. + lymphocyte depletion in rhesus monkeys. J. Virol. 71:4218-4225.
48. Kaslow, R. A., M. Carrington, R. Apple, L. Park, A. Munoz, A. J. Saah, J. J. Goedert, C. Winkler, S. J. O'Brien, C. Rinaldo, R. Detels, W. Blattner, J. Phair, H. Erlich, and D. L. Mann. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-411.
49. Kent, S. J., A. Zhao, S. J. Best, J. D. Chandler, D. B. Boyle, and I. A. Ramshaw. 1998. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:10180-10188.
50. Koopman, G., H. Niphuis, W. Newman, T. K. Kishimoto, V. C. Maino, and J. L. Heeney. 2001. Decreased expression of IL-2 in central and effector CD4 memory cells during progression to AIDS in rhesus macaques. AIDS 15:2359-2369.
51. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
52. Kuroda, M. J., J. E. Schmitz, W. A. Charini, C. E. Nickerson, M. A. Lifton, C. I. Lord, M. A. Forman, and N. L. Letvin. 1999. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 162:5127-5133.
53. Letvin, N. L. 2006. Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 6:930-939.
54. + lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J. Virol. 75:10187- 10199.
55. Loffredo, J. T., J. Maxwell, Y. Qi, C. E. Glidden, G. J. Borchardt, T. Soma, A. T. Bean, D. R. Beal, N. A. Wilson, W. M. Rehrauer, J. D. Lifson, M. Carrington, and D. I. Watkins. 2007. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J. Virol. 81:8827-8832.
56. Lu, B. 2006. The molecular mechanisms that control function and death of effector CD4+ T cells. Immunol. Res. 36:275-282.
57. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171:131-137.
58. Mäkitalo, B., P. Lundholm, J. Hinkula, C. Nilsson, K. Karlen, A. Morner, G. Sutter, V. Erfle, J. L. Heeney, B. Wahren, G. Biberfeld, and R. Thorstensson. 2004. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J. Gen. Virol. 85:2407-2419.
59. McNeil, A. J., P. L. Yap, S. M. Gore, R. P. Brettle, M. McColl, R. Wyld, S. Davidson, R. Weightman, A. M. Richardson, and J. R. Robertson. 1996. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM 89:177-185.
60. Mescher, M. F., J. M. Curtsinger, P. Agarwal, K. A. Casey, M. Gerner, C. D. Hammerbeck, F. Popescu, and Z. Xiao. 2006. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev. 211:81-92.
61. Migueles, S. A., M. S. Sabbaghian, W. L. Shupert, M. P. Bettinotti, F. M. Marincola, L. Martino, C. W. Hallahan, S. M. Selig, D. Schwartz, J. Sullivan, and M. Connors. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 97:2709-2714.
62. Mooij, P., W. M. Bogers, H. Oostermeijer, W. Koornstra, P. J. Ten Haaft, B. E. Verstrepen, G. Van Der Auwera, and J. L. Heeney. 2000. Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J. Virol. 74:4017-4027.
63. Mooij, P., and J. L. Heeney. 2001. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine 20:304-321.
64. mac239 replication. J. Virol. 77:2736-2740.
65. Mwau, M., I. Cebere, J. Sutton, P. Chikoti, N. Winstone, E. G. Wee, T. Beattie, Y. H. Chen, L. Dorrell, H. McShane, C. Schmidt, M. Brooks, S. Patel, J. Roberts, C. Conlon, S. L. Rowland-Jones, J. J. Bwayo, A. J. McMichael, and T. Hanke. 2004. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85:911-919.
66. Myagkikh, M., S. Alipanah, P. D. Markham, J. Tartaglia, E. Paoletti, R. C. Gallo, G. Franchini, and M. Robert-Guroff. 1996. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retrovir. 12:985-992.
67. Nájera, J. L., C. E. Gomez, E. Domingo-Gil, M. M. Gherardi, and M. Esteban. 2006. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J. Virol. 80:6033-6047.
68. Nkolola, J. P., E. G. Wee, E. J. Im, C. P. Jewell, N. Chen, X. N. Xu, A. J. McMichael, and T. Hanke. 2004. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for eastern and central Africa. Gene Ther. 11:1068-1080.
69. Obst, R., H. M. van Santen, D. Mathis, and C. Benoist. 2005. Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. J. Exp. Med. 201:1555-1565.
70. O'Connor, D. H., B. R. Mothe, J. T. Weinfurter, S. Fuenger, W. M. Rehrauer, P. Jing, R. R. Rudersdorf, M. E. Liebl, K. Krebs, J. Vasquez, E. Dodds, J. Loffredo, S. Martin, A. B. McDermott, T. M. Allen, C. Wang, G. G. Doxiadis, D. C. Montefiori, A. Hughes, D. R. Burton, D. B. Allison, S. M. Wolinsky, R. Bontrop, L. J. Picker, and D. I. Watkins. 2003. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J. Virol. 77:9029-9040.
71. Okoye, A., M. Meier-Schellersheim, J. M. Brenchley, S. I. Hagen, J. M. Walker, M. Rohankhedkar, R. Lum, J. B. Edgar, S. L. Planer, A. Legasse, A. W. Sylwester, M. Piatak, Jr., J. D. Lifson, V. C. Maino, D. L. Sodora, D. C. Douek, M. K. Axthelm, Z. Grossman, and L. J. Picker. 2007. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J. Exp. Med. 204:2171-2185.
72. mac-induced immunodeficiency. J. Virol. 76:292-302.
73. Palmowski, M. J., E. M. Choi, I. F. Hermans, S. C. Gilbert, J. L. Chen, U. Gileadi, M. Salio, A. Van Pel, S. Man, E. Bonin, P. Liljestrom, P. R. Dunbar, and V. Cerundolo. 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168:4391-4398.
74. Pantaleo, G., and A. Harari. 2006. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat. Rev. Immunol. 6:417-423.
75. Parish, C. R. 1999. Fluorescent dyes for lymphocyte migration and proliferation studies. Immunol. Cell Biol. 77:499-508.
76. Precopio, M. L., M. R. Betts, J. Parrino, D. A. Price, E. Gostick, D. R. Ambrozak, T. E. Asher, D. C. Douek, A. Harari, G. Pantaleo, R. Bailer, B. S. Graham, M. Roederer, and R. A. Koup. 2007. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. J. Exp. Med. 204:1405-1416.
77. Reimann, K. A., J. T. Li, R. Veazey, M. Halloran, I. W. Park, G. B. Karlsson, J. Sodroski, and N. L. Letvin. 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:6922-6928.
78. Reimann, K. A., J. T. Li, G. Voss, C. Lekutis, K. Tenner-Racz, P. Racz, W. Lin, D. C. Montefiori, D. E. Lee-Parritz, Y. Lu, R. G. Collman, J. Sodroski, and N. L. Letvin. 1996. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70:3198-3206.
79. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100:4144-4149.
80. Robinson, H. L., D. C. Montefiori, R. P. Johnson, K. H. Manson, M. L. Kalish, J. D. Lifson, T. A. Rizvi, S. Lu, S. L. Hu, G. P. Mazzara, D. L. Panicali, J. G. Herndon, R. Glickman, M. A. Candido, S. L. Lydy, M. S. Wyand, and H. M. McClure. 1999. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5:526-534.
81. + T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J. Virol. 76:4251-4259.
82. Sadagopal, S., R. R. Amara, D. C. Montefiori, L. S. Wyatt, S. I. Staprans, N. L. Kozyr, H. M. McClure, B. Moss, and H. L. Robinson. 2005. Signature for long-term vaccine-mediated control of a simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. J. Virol. 79:3243-3253.
83. Santra, S., D. H. Barouch, B. Korioth-Schmitz, C. I. Lord, G. R. Krivulka, F. Yu, M. H. Beddall, D. A. Gorgone, M. A. Lifton, A. Miura, V. Philippon, K. Manson, P. D. Markham, J. Parrish, M. J. Kuroda, J. E. Schmitz, R. S. Gelman, J. W. Shiver, D. C. Montefiori, D. Panicali, and N. L. Letvin. 2004. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc. Natl. Acad. Sci. USA 101:11088-11093.
84. Santra, S., Y. Sun, J. G. Parvani, V. Philippon, M. S. Wyand, K. Manson, A. Gomez-Yafal, G. Mazzara, D. Panicali, P. D. Markham, D. C. Montefiori, and N. L. Letvin. 2007. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J. Virol. 81:8563-8570.
85. Schluns, K. S., K. Williams, A. Ma, X. X. Zheng, and L. Lefrancois. 2002. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J. Immunol. 168:4827-4831.
86. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb, M. A. Forman, D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A. Reimann. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860.
87. Siemens, D. R., S. Crist, J. C. Austin, J. Tartaglia, and T. L. Ratliff. 2003. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model. J. Urol. 170:979-984.
88. Su, L., M. Graf, Y. Zhang, H. von Briesen, H. Xing, J. Kostler, H. Melzl, H. Wolf, Y. Shao, and R. Wagner. 2000. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B′) recombinant strain in China. J. Virol. 74:11367-11376.
89. + T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection. J. Virol. 81:8009-8015.
90. Sun, Y., J. E. Schmitz, A. P. Buzby, B. R. Barker, S. S. Rao, L. Xu, Z. Y. Yang, J. R. Mascola, G. J. Nabel, and N. L. Letvin. 2006. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J. Virol. 80:10950-10956.
91. Sundrud, M. S., and A. Rao. 2007. New twists of T cell fate: control of T cell activation and tolerance by TGF-beta and NFAT. Curr. Opin. Immunol. 19:287-293.
92. Sutter, G., and C. Staib. 2003. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3:263-271.
93. Tartaglia, J., W. I. Cox, S. Pincus, and E. Paoletti. 1994. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. Dev. Biol. Stand. 82:125-129.
94. Tartaglia, J., M. E. Perkus, J. Taylor, E. K. Norton, J. C. Audonnet, W. I. Cox, S. W. Davis, J. van der Hoeven, B. Meignier, M. Riviere, et al. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-232.
95. Ten Haaft, P., B. Verstrepen, K. Uberla, B. Rosenwirth, and J. Heeney. 1998. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J. Virol. 72:10281-10285.
96. Wada, K., S. Aota, R. Tsuchiya, F. Ishibashi, T. Gojobori, and T. Ikemura. 1990. Codon usage tabulated from the GenBank genetic sequence data. Nucleic Acids Res. 18(Suppl.):2367-2411.
97. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
98. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Komarova, M. A. Nowak, B. H. Hahn, P. D. Kwong, and G. M. Shaw. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
99. mac239. J. Virol. 80:5875-5885.
100. mac239 replication. J. Virol. 80:5074-5077.
101. Zimmerli, S. C., A. Harari, C. Cellerai, F. Vallelian, P. A. Bart, and G. Pantaleo. 2005. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA 102:7239-7244.